Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.64 |
| ▸ | NNMT | P40261 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661280 | 1.00 | HCAR3 (0.64) | HCAR3NNMTGSK3BPTPN1HCAR2 | |
| Bromide SCHEMBL16753536 | 0.98 | HCAR3 (0.62) | HCAR3NNMTGSK3BPTPN1HCAR2 | |
| SCHEMBL31661260 | 0.83 | HCAR3 (0.69) | HCAR3NNMTGSK3BPTPN1HCAR2 | |
| SCHEMBL1203341 | 0.83 | PTK2 (0.54) | HCAR3NNMTGSK3BPTPN1 | |
| SCHEMBL24285432 | 0.83 | HCAR3 (0.64) | HCAR3NNMTHCAR2 | |
| SCHEMBL6074331 | 0.81 | HDAC3 (0.47) | HCAR3NNMTGSK3BPTPN1HCAR2 | |
| SCHEMBL30320778 | 0.81 | GSK3B (0.46) | HCAR3NNMTGSK3BPTPN1 | |
| SCHEMBL25702957 | 0.81 | GSK3B (0.46) | HCAR3NNMTGSK3BPTPN1 | |
| SCHEMBL9772954 | 0.80 | ALDH1A1 (0.51) | HCAR3GSK3BHCAR2 | |
| SCHEMBL10084182 | 0.79 | HCAR3 (0.41) | HCAR3NNMTGSK3BPTPN1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | DHFR, PRMT1, PRMT7 | HCAR3 4490/4885NNMT 28/4885GSK3B 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.